Vaccine

Journal

Publication Venue For

  • HPV vaccine uptake among daughters of Latinx immigrant mothers: Findings from a cluster randomized controlled trial of a community-based, culturally relevant intervention.  38:4125-4134. 2020
  • A randomized phase II trial to compare safety and immunogenicity of the MVA-BN smallpox vaccine at various doses in adults with a history of AIDS.  38:2600-2607. 2020
  • Peripheral CD4 T follicular cells induced by a conjugated pneumococcal vaccine correlate with enhanced opsonophagocytic antibody responses in younger individuals.  38:1778-1786. 2020
  • Gonococcal vaccines: Public health value and preferred product characteristics; report of a WHO global stakeholder consultation, January 2019 2020
  • Vaccination against the human cytomegalovirus.  37:7437-7442. 2019
  • CpG ODN G9.1 as a novel nasal ODN adjuvant elicits complete protection from influenza virus infection without causing inflammatory immune responses.  37:5382-5389. 2019
  • A Phase 1 dose escalating study of double mutant heat-labile toxin LTR192G/L211A (dmLT) from Enterotoxigenic Escherichia coli (ETEC) by sublingual or oral immunization.  37:602-611. 2019
  • The diversity of the proline-rich domain of pneumococcal surface protein A (PspA): Potential relevance to a broad-spectrum vaccine.  36:6834-6843. 2018
  • Effect of prior vaccination on carriage rates of Streptococcus pneumoniae in older adults: A longitudinal surveillance study.  36:4304-4310. 2018
  • Barriers and facilitators to HPV vaccination among rural Alabama adolescents and their caregivers.  36:4126-4133. 2018
  • Lipopolysaccharide-specific memory B cell responses to an attenuated live cholera vaccine are associated with protection against Vibrio cholerae infection.  36:2768-2773. 2018
  • Randomized clinical trial of a single versus a double dose of 13-valent pneumococcal conjugate vaccine in adults 55 through 74 years of age previously vaccinated with 23-valent pneumococcal polysaccharide vaccine.  36:606-614. 2018
  • Evaluating interest in an influenza A(H5N1) vaccine among laboratory workers who work with highly-pathogenic avian influenza viruses in the United States.  36:306-312. 2018
  • Nasal delivery of Protollin-adjuvanted H5N1 vaccine induces enhanced systemic as well as mucosal immunity in mice.  35:3318-3325. 2017
  • Rotavirus immunization: Global coverage and local barriers for implementation.  35:1637-1644. 2017
  • Improving the selection and development of influenza vaccine viruses – Report of a WHO informal consultation on improving influenza vaccine virus selection, Hong Kong SAR, China, 18–20 November 2015.  35:1104-1109. 2017
  • Pneumococcal pep27 mutant immunization stimulates cytokine secretion and confers long-term immunity with a wide range of protection, including against non-typeable strains.  34:6481-6492. 2016
  • Systemic Lupus Erythematosus: Case definition and guidelines for data collection, analysis, and presentation of immunization safety data.  34:6572-6581. 2016
  • Vasculitis as an adverse event following immunization – Systematic literature review.  34:6641-6651. 2016
  • Characterization of serum antibodies from women immunized with Gardasil: A study of HPV-18 infection of primary human keratinocytes.  34:3171-3177. 2016
  • Effects of Repeated Annual Inactivated Influenza Vaccination among Healthcare Personnel on Serum Hemagglutinin Inhibition Antibody Response to A/Perth/16/2009 (H3N2)-like virus during 2010-11.  34:981-988. 2016
  • A highly immunogenic vaccine against A/H7N9 influenza virus.  34:744-749. 2016
  • Comparability of neuraminidase inhibition antibody titers measured by enzyme-linked lectin assay (ELLA) for the analysis of influenza vaccine immunogenicity.  34:458-465. 2016
  • Strengthening the influenza vaccine virus selection and development process. Report of the 3rd WHO Informal Consultation for Improving Influenza Vaccine Virus Selection held at WHO headquarters, Geneva, Switzerland, 1-3 April 2014..  33:4368-4382. 2015
  • AS03-adjuvanted H7N1 detergent-split virion vaccine is highly immunogenic in unprimed mice and induces cross-reactive antibodies to emerged H7N9 and additional H7 subtypes.  33:3784-3787. 2015
  • A bivalent conjugate vaccine containing PspA families 1 and 2 has the potential to protect against a wide range of Streptococcus pneumoniae strains and Salmonella Typhi.  33:783-788. 2015
  • Preparation and testing of a Vi conjugate vaccine using pneumococcal surface protein A (PspA) from Streptococcus pneumoniae as the carrier protein.  32:5755-5760. 2014
  • Impaired serotype-specific immune function following pneumococcal vaccination in infants with prior carriage.  32:2321-2327. 2014
  • Safety and immunogenicity of a plant-produced recombinant monomer hemagglutinin-based influenza vaccine derived from influenza A (H1N1)pdm09 virus: A Phase 1 dose-escalation study in healthy adults.  32:2251-2259. 2014
  • Cross-neutralizing antibodies elicited by the Cervarix® human papillomavirus vaccine display a range of Alpha-9 inter-type specificities.  32:1139-1146. 2014
  • Intranasal seasonal influenza vaccine and a TLR-3 agonist, rintatolimod, induced cross-reactive IgA antibody formation against avian H5N1 and H7N9 influenza HA in humans.  32:5490-5495. 2014
  • Live attenuated H7N7 influenza vaccine primes for a vigorous antibody response to inactivated H7N7 influenza vaccine.  32:6798-6804. 2014
  • Protective properties of a fusion pneumococcal surface protein A (PspA) vaccine against pneumococcal challenge by five different PspA clades in mice.  32:5607-5613. 2014
  • A modified surface killing assay (MSKA) as a functional in vitro assay for identifying protective antibodies against pneumococcal surface protein A (PspA).  32:39-47. 2013
  • Priorities for CMV vaccine development.  32:4-10. 2013
  • A chimeric Sindbis-based vaccine protects cynomolgus macaques against a lethal aerosol challenge of eastern equine encephalitis virus.  31:1464-1470. 2013
  • Low opsonic activity to the infecting serotype in pediatric patients with invasive pneumococcal disease.  31:845-849. 2013
  • A genome-wide association study of host genetic determinants of the antibody response to Anthrax Vaccine Adsorbed.  30:4778-4784. 2012
  • Streptococcus pneumoniae pep27 mutant as a live vaccine for serotype-independent protection in mice.  30:2008-2019. 2012
  • CCL5-independent helper T lymphocyte responses to immuno-dominant pneumococcal surface protein A epitopes.  30:1181-1190. 2012
  • A novel combined adjuvant for nasal delivery elicits mucosal immunity to influenza in aging.  30:803-812. 2012
  • Cationic liposome-DNA complexes (CLDC) adjuvant enhances the immunogenicity and cross-protective efficacy of a pre-pandemic influenza A H5N1 vaccine in mice.  30:254-264. 2012
  • Intranasal administration of a flagellin-adjuvanted inactivated influenza vaccine enhances mucosal immune responses to protect mice against lethal infection.  30:466-474. 2012
  • Reproducibility of serology assays for pandemic influenza H1N1: Collaborative study to evaluate a candidate WHO International Standard.  30:210-217. 2012
  • Global prevention and management of human papillomavirus related diseases: The pressing challenges and the compelling opportunities.  30. 2012
  • The 13-valent pneumococcal conjugate vaccine (PCV13) elicits cross-functional opsonophagocytic killing responses in humans to Streptococcus pneumoniae serotypes 6C and 7A.  29:7207-7211. 2011
  • Delta inulin polysaccharide adjuvant enhances the ability of split-virion H5N1 vaccine to protect against lethal challenge in ferrets.  29:6242-6251. 2011
  • Mucosal immune features to phosphorylcholine by nasal Flt3 ligand cDNA-based vaccination.  29:5747-5757. 2011
  • Characterization of the replivax platform for replication-defective flavivirus vaccines.  29:5184-5194. 2011
  • Lower peripheral blood CD14+ monocyte frequency and higher CD34+ progenitor cell frequency are associated with HBV vaccine induced response in HIV infected individuals.  29:3558-3563. 2011
  • Efficacy of seasonal live attenuated influenza vaccine against virus replication and transmission of a pandemic 2009 H1N1 virus in ferrets.  29:2887-2894. 2011
  • Erratum to " Effective induction of protective systemic immunity with nasally administered vaccines adjuvanted with IL-1" [Vaccine 28 (42) (2010) 6901-6914].  29:2821. 2011
  • A phase I trial of preventive HIV vaccination with heterologous poxviral-vectors containing matching HIV-1 inserts in healthy HIV-uninfected subjects.  29:1948-1958. 2011
  • Opsonophagocytic activity following a reduced dose 7-valent pneumococcal conjugate vaccine infant primary series and 23-valent pneumococcal polysaccharide vaccine at 12 months of age.  29:535-544. 2011
  • The development of vaccine viruses against pandemic A(H1N1) influenza.  29:1836-1843. 2011
  • Regulation of the activity of an adeno-associated virus vector cancer vaccine administered with synthetic Toll-like receptor agonists.  28:7837-7843. 2010
  • Effective induction of protective systemic immunity with nasally administered vaccines adjuvanted with IL-1.  28:6901-6914. 2010
  • Immune response to hepatitis B vaccine in HIV-infected subjects using granulocyte-macrophage colony-stimulating factor (GM-CSF) as a vaccine adjuvant: ACTG study 5220.  28:5597-5604. 2010
  • Role of Toll-like receptors in host responses to a virulence antigen of Streptococcus mutans expressed by a recombinant, attenuated Salmonella vector vaccine.  28:4928-4936. 2010
  • Mucosal HIV vaccines: A holy grail or a dud?.  28:4015-4026. 2010
  • Peak frequencies of circulating human influenza-specific antibody secreting cells correlate with serum antibody response after immunization.  28:3582-3587. 2010
  • Attitudes toward and intention to receive the human papilloma virus (HPV) vaccination and intention to use condoms among female Korean college students.  28:811-816. 2010
  • A genetically engineered adenovirus vector targeted to CD40 mediates transduction of canine dendritic cells and promotes antigen-specific immune responses in vivo.  27:7116-7124. 2009
  • Oral MucoRice expressing double-mutant cholera toxin A and B subunits induces toxin-specific neutralising immunity.  27:5982-5988. 2009
  • Co-administration of cholera toxin and apple polyphenol extract as a novel and safe mucosal adjuvant strategy.  27:4808-4817. 2009
  • Chimeric alphavirus vaccine candidates protect mice from intranasal challenge with western equine encephalitis virus.  27:4309-4319. 2009
  • KMP-11 DNA immunization significantly protects against L. donovani infection but requires exogenous IL-12 as an adjuvant for comparable protection against L. major.  27:1306-1316. 2009
  • Pneumococcal vaccination in older adults induces antibodies with low opsonic capacity and reduced antibody potency.  26:5521-5526. 2008
  • Chimeric alphavirus vaccine candidates for chikungunya.  26:5030-5039. 2008
  • Prospects for use of interleukin-12 as a mucosal adjuvant for vaccination of humans to protect against respiratory pneumococcal infection.  26:4893-4903. 2008
  • A combination of Flt3 ligand cDNA and CpG ODN as nasal adjuvant elicits NALT dendritic cells for prolonged mucosal immunity.  26:4849-4859. 2008
  • Combination of treatment with death receptor 5-specific antibody with therapeutic HPV DNA vaccination generates enhanced therapeutic anti-tumor effects.  26:4314-4319. 2008
  • Delivery of DNA HIV-1 vaccine to the liver induces high and long-lasting humoral immune responses.  26:1541-1551. 2008
  • Low prevalence of recently discovered pneumococcal serotype 6C isolates among healthy Dutch children in the pre-vaccination era.  26:449-450. 2008
  • Genomic differences of Vaccinia virus clones from Dryvax smallpox vaccine: The Dryvax-like ACAM2000 and the mouse neurovirulent Clone-3.  25:8807-8832. 2007
  • Chimeric Sindbis/eastern equine encephalitis vaccine candidates are highly attenuated and immunogenic in mice.  25:7573-7581. 2007
  • Long- and short-time immunological memory in different strains of mice given nasally an adjuvant-combined nasal influenza vaccine.  25:6975-6980. 2007
  • HIV-189.6 Gag expressed from a replication competent HSV-1 vector elicits persistent cellular immune responses in mice.  25:6764-6773. 2007
  • Intranasal immunization with influenza virus and Korean mistletoe lectin C (KML-C) induces heterosubtypic immunity in mice.  25:6359-6366. 2007
  • Role of CD80 and CD86 in host immune responses to the recombinant hemagglutinin domain of Porphyromonas gingivalis gingipain and in the adjuvanticity of cholera toxin B and monophosphoryl lipid A.  25:6201-6210. 2007
  • A single intranasal immunization with inactivated influenza virus and α-galactosylceramide induces long-term protective immunity without redirecting antigen to the central nervous system.  25:5189-5198. 2007
  • Comparison of neutralising antibody assays for detection of antibody to influenza A/H3N2 viruses: An international collaborative study.  25:4056-4063. 2007
  • Immunogenicity of varying dosages of 7-valent pneumococcal polysaccharide-protein conjugate vaccine in seniors previously vaccinated with 23-valent pneumococcal polysaccharide vaccine.  25:4029-4037. 2007
  • Durable HIV-1 antibody and T-cell responses elicited by an adjuvanted multi-protein recombinant vaccine in uninfected human volunteers.  25:510-518. 2007
  • Characterization of an influenza A H5N2 reassortant as a candidate for live-attenuated and inactivated vaccines against highly pathogenic H5N1 viruses with pandemic potential.  24:6859-6866. 2006
  • Cross-protective immunity in mice induced by live-attenuated or inactivated vaccines against highly pathogenic influenza A (H5N1) viruses.  24:6588-6593. 2006
  • Interferon and other proinflamatory cytokine responses in vitro following infection with wild-type and cold-adapted reassortant influenza viruses.  24:6581-6584. 2006
  • Immunogenicity of Salmonella vector vaccines expressing SBR of Streptococcus mutans under the control of a T7-nirB (dual) promoter system.  24:5003-5015. 2006
  • Genetically engineered herpes simplex viruses that express IL-12 or GM-CSF as vaccine candidates.  24:1644-1652. 2006
  • Uneven distribution of MHC class II epitopes within the influenza virus.  24:457-467. 2006
  • European Union and EDCTP strategy in the global context: Recommendations for preventive HIV/AIDS vaccines research.  23:5551-5556. 2005
  • Effectiveness of the B subunit of cholera toxin in potentiating immune responses to the recombinant hemagglutinin/adhesin domain of the gingipain Kgp from Porphyromonas gingivalis.  23:4734-4744. 2005
  • Antibodies to the pneumococcal surface protein A, PspA, can be produced in splenectomized mice and can protect splenectomized mice from infection with Streptococcus pneumoniae.  23:4257-4262. 2005
  • Safety of varying dosages of 7-valent pneumococcal protein conjugate vaccine in seniors previously vaccinated with 23-valent pneumococcal polysaccharide vaccine.  23:3697-3703. 2005
  • Immune response versus mucosal tolerance to mucosally administered antigens.  23:1800-1803. 2005
  • A DNA vaccine encoding genetic fusions of carcinoembryonic antigen (CEA) and granulocyte/macrophage colony-stimulating factor (GM-CSF).  23:1273-1283. 2005
  • Safety and immunogenicity of adenovirus-vectored nasal and epicutaneous influenza vaccines in humans.  23:1029-1036. 2005
  • Poliovirus replicons encoding the B subunit of Helicobacter pylori urease protect mice against H. pylori infection.  23:901-909. 2005
  • Characterization of antibodies to PspA and PsaA in adults over 50 years of age with invasive pneumococcal disease.  23:789-793. 2004
  • Development of experimental carbohydrate-conjugate vaccines composed of Streptococcus pneumoniae capsular polysaccharides and the universal helper T-lymphocyte epitope (PADRE®).  22:2362-2367. 2004
  • Immunization of colorectal cancer patients with recombinant baculovirus-derived KSA (Ep-CAM) formulated with monophosphoryl lipid a in liposomal emulsion, with and without granulocyte-macrophage colony-stimulating factor.  22:773-780. 2004
  • Effectiveness of the quillaja saponin semi-synthetic analog GPI-0100 in potentiating mucosal and systemic responses to recombinant HagB from Porphyromonas gingivalis.  21:4459-4471. 2003
  • Generation and evaluation of a high-growth reassortant H9N2 influenza A virus as a pandemic vaccine candidate.  21:1974-1979. 2003
  • Construction and characterisation of O139 cholera vaccine candidates..  21:1282-1291. 2003
  • Fractionation, structural studies, and immunological characterization of the semi-synthetic Quillaja saponins derivative GPI-0100.  21:3961-3971. 2003
  • Immune intervention strategies for HIV-1 infection of humans in the SIV macaque model.  20. 2002
  • Quillaja saponin adjuvants: Derivatives formed under sub-optimal conditions.  20:3237-3238. 2002
  • A novel chimeric Rev, Tat, and Nef (Retanef) antigen as a component of an SIV/HIV vaccine.  20:3171-3186. 2002
  • A dilemma for mucosal vaccination: Efficacy versus toxicity using enterotoxin-based adjuvants.  20:2431-2438. 2002
  • Mutant Escherichia coli heat-labile enterotoxin [LT(R192G)] enhances protective humoral and cellular immune responses to orally administered inactivated influenza vaccine.  20:1019-1029. 2002
  • A human volunteer challenge model using frozen bacteria of the new epidemic serotype, V. cholerae O139 in Thai volunteers.  20:920-925. 2001
  • Highly purified mutant E112K of cholera toxin elicits protective lung mucosal immunity to diphtheria toxin.  20:756-762. 2001
  • A Phase I safety and immunogenicity trial of UBI® microparticulate monovalent HIV-1 MN oral peptide immunogen with parenteral boost in HIV-1 seronegative human subjects.  19:3033-3042. 2001
  • IL-12-mediated increases in protection elicited by pneumococcal and meningococcal conjugate vaccines.  19:2020-2028. 2001
  • Nasal immunization with E. coli verotoxin 1 (VT1)-B subunit and a nontoxic mutant of cholera toxin elicits serum neutralizing antibodies.  19:2061-2070. 2001
  • QS-21 promotes an adjuvant effect allowing for reduced antigen dose during HIV-1 envelope subunit immmunization in humans.  19:2080-2091. 2001
  • Safety and immunogenicity of a recombinant hemagglutinin vaccine for H5 influenza in humans.  19:1732-1737. 2001
  • Strategies of immunization against mucosal infections.  19. 2000
  • The potential for using protein vaccines to protect against otitis media caused by Streptococcus pneumoniae.  19. 2000
  • Erratum: Competition among Streptococcus pneumoniae for intranasal colonization in amouse model (Vaccine (2000) 18 (2895-2901) PII: S0264410X00000463).  19:598. 2000
  • Immunogenicity and efficacy of Russian live attenuated and US inactivated influenza vaccines used alone and in combination in nursing home residents.  19:308-318. 2000
  • Development of semisynthetic triterpenoid saponin derivatives with immune stimulating activity.  18:3141-3151. 2000
  • Competition among Streptococcus pneumoniae for intranasal colonization in a mouse model.  18:2895-2901. 2000
  • Development of a multi-specificity opsonophagocytic killing assay.  18:2768-2771. 2000
  • A nonionic block co-polymer adjuvant (CRL1005) enhances the immunogenicity and protective efficacy of inactivated influenza vaccine in young and aged mice.  18:2177-2187. 2000
  • Immunization of healthy adults with a single recombinant pneumococcal surface protein A (PspA) variant stimulates broadly cross-reactive antibodies to heterologous PspA molecules.  18:1743-1754. 2000
  • Purification and characterization of Streptococcus pneumoniae palmitoylated pneumococcal surface adhesin A expressed in Escherichia coli.  18:1811-1821. 2000
  • Mucosal vaccination and immune responses in the elderly.  18:1675-1680. 2000
  • The potential to use PspA and other pneumococcal proteins to elicit protection against pneumococcal infection.  18:1707-1711. 2000
  • Poliovirus replicons encoding the B subunit of Helicobacter pylori urease elicit a Th1 associated immune response.  17:2384-2391. 1999
  • Modified M2 proteins produce heterotypic immunity against influenza A virus.  17:2237-2244. 1999
  • Induction of protective immune responses against venezuelan equine encephalitis (VEE) virus aerosol challenge with microencapsulated VEE virus vaccine.  16:1314-1323. 1998
  • Regulation of the antibody repertoire through control of HCDR3 diversity.  16:1383-1390. 1998
  • CpG DNA, a novel immune enhancer for systemic and mucosal immunization with influenza virus.  16:1216-1224. 1998
  • Modulation of immunologic responses to HIV-1(MN) recombinant gp160 vaccine by dose and schedule of administration.  16:493-506. 1998
  • Immunization of mice with poliovirus replicons expressing the C-fragment of tetanus toxin protects against lethal challenge with tetanus toxin.  15:257-264. 1997
  • Construction and oral immunogenicity of a Salmonella typhimurium strain expressing a streptococcal adhesin linked to the A2/B subunits of cholera toxin.  14:1545-1548. 1996
  • Tagging a Vibrio cholerae El Tor candidate vaccine strain by disruption of its hemagglutinin/protease gene using a novel reporter enzyme: Clostridium thermocellum endoglucanase A..  14:1517-1522. 1996
  • Association of placental transfer of anti-Haemophilus influenzae type b polysaccharide antibodies with their V regions.  14:1219-1222. 1996
  • Oral immunization with recombinant Salmonella typhimurium expressing surface protein antigen A (SpaA) of Streptococcus sobrinus: Effects of the Salmonella virulence plasmid on the induction of protective and sustained humoral responses in rats.  14:868-878. 1996
  • PspA, a protection-eliciting pneumococcal protein: Immunogenicity of isolated native PspA in mice.  14:858-867. 1996
  • Enhancement of protective immune responses to Venezuelan equine encephalitis (VEE) virus with microencapsulated vaccine.  13:1411-1420. 1995
  • Human immune responses to influenza virus vaccines administered by systemic or mucosal routes.  13:1006-1012. 1995
  • Immune responses induced by administration of encapsidated poliovirus replicons which express HIV-1 gag and envelope proteins.  13:1013-1022. 1995
  • Protection of mice against influenza A virus challenge by vaccination with baculovirus-expressed M2 protein.  13:1399-1402. 1995
  • Helper Th1 and Th2 cell responses following mucosal or systemic immunization with cholera toxin.  12:903-911. 1994
  • Murine model for evaluation of protective immunity to influenza virus.  11:55-60. 1993
  • The mucosal immune system: from fundamental concepts to vaccine development.  10:75-88. 1992
  • Murine helper T lymphocyte response to influenza virus: recognition of haemagglutinin by subtype-specific and cross-reactive T cell clones.  3:257-262. 1985
  • International Standard Serial Number (issn)

  • 0264-410X
  • Electronic International Standard Serial Number (eissn)

  • 1873-2518